2023
Combining Low-Dose Computer-Tomography-Based Radiomics and Serum Metabolomics for Diagnosis of Malignant Nodules in Participants of Lung Cancer Screening Studies
Zyla J, Marczyk M, Prazuch W, Sitkiewicz M, Durawa A, Jelitto M, Dziadziuszko K, Jelonek K, Kurczyk A, Szurowska E, Rzyman W, Widłak P, Polanska J. Combining Low-Dose Computer-Tomography-Based Radiomics and Serum Metabolomics for Diagnosis of Malignant Nodules in Participants of Lung Cancer Screening Studies. Biomolecules 2023, 14: 44. PMID: 38254644, PMCID: PMC10813699, DOI: 10.3390/biom14010044.Peer-Reviewed Original ResearchSerum metabolomicsComputed tomography lung cancer screeningLow-dose computed tomography (LDCT) lung cancer screeningLung cancer screening studyTomography lung cancer screeningLung cancer screeningCancer screening studyLung cancer diagnosisCollected cohortCancer screeningLung cancerSerum metabolomeBenign lesionsPulmonary nodulesMetabolomic evaluationAuxiliary biomarkerLogistic regressionDiagnosisCancer diagnosisLung nodulesMalignant nodulesScreening studyPatientsRadiomicsMolecular featuresmiR-122 and miR-21 are Stable Components of miRNA Signatures of Early Lung Cancer after Validation in Three Independent Cohorts
Zyla J, Dziadziuszko R, Marczyk M, Sitkiewicz M, Szczepanowska M, Bottoni E, Veronesi G, Rzyman W, Polanska J, Widlak P. miR-122 and miR-21 are Stable Components of miRNA Signatures of Early Lung Cancer after Validation in Three Independent Cohorts. Journal Of Molecular Diagnostics 2023, 26: 37-48. PMID: 37865291, DOI: 10.1016/j.jmoldx.2023.09.010.Peer-Reviewed Original ResearchConceptsEarly lung cancerLung cancerLung cancer screening studyMiR-122MiR-21MiRNA signatureCancer screening studyLung cancer developmentPlasma miRNA signatureScreening studyIndependent cohortDiagnostic biomarkersPotential biomarkersCancer typesCohortCancer developmentCancerHealthy participantsMiR-144MiRNA panelDiagnostic potentialBiomarkersAdenocarcinomaDifferent cohortsMiRNAs
2019
Lung cancer survival and comorbidities in lung cancer screening participants of the Gdańsk screening cohort
Ostrowski M, Marczyk M, Dziedzic R, Jelitto-Górska M, Marjański T, Pisiak S, Jędrzejczyk T, Polańska J, Zdrojewski T, Wojtyniak B, Rzyman W. Lung cancer survival and comorbidities in lung cancer screening participants of the Gdańsk screening cohort. European Journal Of Public Health 2019, 29: 1114-1117. PMID: 31004154, DOI: 10.1093/eurpub/ckz052.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseLung cancer screening programsCancer screening programsCardiovascular diseaseDiabetes mellitusLung cancerScreening programLung cancer detection rateMedical eventsModifiable risk factorsLung cancer survivalObstructive pulmonary diseaseLung cancer patientsCancer detection rateHealth care providersHealth care systemWorld Health OrganizationScreening groupHeavy smokersPulmonary diseaseScreening cohortCancer patientsCancer survivalRisk factorsCare providers
2017
Serum lipid profile discriminates patients with early lung cancer from healthy controls
Ros-Mazurczyk M, Jelonek K, Marczyk M, Binczyk F, Pietrowska M, Polanska J, Dziadziuszko R, Jassem J, Rzyman W, Widlak P. Serum lipid profile discriminates patients with early lung cancer from healthy controls. Lung Cancer 2017, 112: 69-74. PMID: 29191603, DOI: 10.1016/j.lungcan.2017.07.036.Peer-Reviewed Original ResearchConceptsEarly lung cancerSerum lipid profileLung cancerNegative predictive valuePredictive valueCancer patientsLipid profileComputed tomography lung cancer screeningLow-dose computed tomography (LDCT) lung cancer screeningTomography lung cancer screeningEarly-stage lung cancerHealthy participantsEarly lung cancer patientsLow-dose computed tomographyHigh-risk smokersLung cancer screeningLung cancer patientsStage lung cancerMaximum negative predictive valueBlood-based biomarkersPositive predictive valueSerum lipidomeCancer screeningHealthy controlsSerum signatureStage I non-small-cell lung cancer: long-term results of lobectomy versus sublobar resection from the Polish National Lung Cancer Registry†
Dziedzic R, Żurek W, Marjański T, Rudziński P, Orłowski TM, Sawicka W, Marczyk M, Polańska J, Rzyman W. Stage I non-small-cell lung cancer: long-term results of lobectomy versus sublobar resection from the Polish National Lung Cancer Registry†. European Journal Of Cardio-Thoracic Surgery 2017, 52: 363-369. PMID: 28402455, DOI: 10.1093/ejcts/ezx092.Peer-Reviewed Original ResearchConceptsStage I NSCLCLung Cancer RegistryWedge resectionCell lung cancerOverall survivalSurvival rateCancer RegistryLung cancerCox proportional hazard ratiosPropensity score-matched analysisProportional hazard ratiosGroup of patientsTreatment of patientsLong-term resultsMethod of resectionLobar resectionHazard ratioSublobar resectionMediastinal lymphadenectomySurgical treatmentPatient groupRetrospective analysisSegmentectomyLobectomyStudy group
2016
Serum mass profile signature as a biomarker of early lung cancer
Widlak P, Pietrowska M, Polanska J, Marczyk M, Ros-Mazurczyk M, Dziadziuszko R, Jassem J, Rzyman W. Serum mass profile signature as a biomarker of early lung cancer. Lung Cancer 2016, 99: 46-52. PMID: 27565913, DOI: 10.1016/j.lungcan.2016.06.011.Peer-Reviewed Original ResearchConceptsEarly lung cancerLung cancerNegative predictive valuePredictive valueComputed tomographyEarly-stage lung cancerLow-dose computed tomographyIndeterminate pulmonary nodulesStage lung cancerPotential clinical usefulnessPositive predictive valueValidation cohortHealthy controlsClinical usefulnessDiscovery cohortBlood samplesIndependent cohortWeight serum fractionsPulmonary nodulesIndependent sample setCancerPatientsHealthy participantsMolecular biomarkersCohort
2011
Comparison of peptide cancer signatures identified by mass spectrometry in serum of patients with head and neck, lung and colorectal cancers: association with tumor progression.
Pietrowska M, Polańska J, Suwiński R, Wideł M, Rutkowski T, Marczyk M, Domińczyk I, Ponge L, Marczak L, Polański A, Widłak P. Comparison of peptide cancer signatures identified by mass spectrometry in serum of patients with head and neck, lung and colorectal cancers: association with tumor progression. International Journal Of Oncology 2011, 40: 148-56. PMID: 21894432, DOI: 10.3892/ijo.2011.1186.Peer-Reviewed Original ResearchConceptsLung cancer samplesCancer samplesHealthy donorsSerum proteomeNon-small cell lung cancerNeck squamous cell cancerSquamous cell cancerCell lung cancerAdvanced cancer casesSera of patientsColorectal cancer samplesCancer signaturesInter-group analysisPeptide signaturesCell cancerClinical stageColorectal cancerCancer patientsLung cancerNeck cancerColorectal adenocarcinomaCancer casesSerum amyloidHealthy volunteersBlood samples